Durham, United States
HemoSonics is a groundbreaking company in the field of point-of-care Viscoelastic hemostasis testing. Their Quantra® QPlus® System is designed to provide rapid, accurate, and easily understandable results, enabling clinicians to make informed transfusion decisions more quickly, particularly in critical time-sensitive situations. With De Novo marketing authorization in the USA, this cartridge-based POC VET system is intended for assessing the coagulation status of perioperative patients at the point of care.
Founded in 2004, HemoSonics operates in the Biotechnology and Health Care industries, with its headquarters located in the United States. The company secured a $15.00M Venture Round investment on 15 February 2017.
With its innovative approach to bleeding management and point-of-care testing, HemoSonics presents substantial potential in revolutionizing transfusion decisions and improving patient care outcomes.
NanoDx, Inc.
